Early Feasibility Study of the CardiAQ™ TMVI System (Transfemoral and Transapical DS)
| Status: | Recruiting |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/26/2016 |
| Start Date: | August 2015 |
| End Date: | July 2021 |
| Contact: | Paul Cornelison |
| Phone: | 949-537-3842 |
Early Feasibility Study of the CardiAQ™ Transcatheter Mitral Valve Implantation (TMVI) System (Transfemoral and Transapical Delivery Systems)
The purpose of the study is to generate early US feasibility data of the CardiAQ™
Transcatheter Mitral Valve Implant System.
The study will enroll patients with moderate to severe mitral valve regurgitation who are
considered high risk for mortality and morbidity from conventional open-heart surgery.
Transcatheter Mitral Valve Implant System.
The study will enroll patients with moderate to severe mitral valve regurgitation who are
considered high risk for mortality and morbidity from conventional open-heart surgery.
Early feasibility study - multi-center, prospective, single-arm, and non-randomized study
without concurrent or historical controls.
The primary objective of the study is to generate early feasibility data for the CardiAQ™
Transcatheter Mitral Valve Implant System with the Transfemoral and Transapical Delivery
Systems for the treatment of moderate to severe mitral valve regurgitation in patients who
are considered high risk for mortality and morbidity from conventional open-heart surgery.
The secondary objectives of the study are to evaluate the long-term safety of the device and
the effects of the device on performance, functional, quality of life parameters, and
technical, device, procedural, and individual patient successes.
The study is to be performed at a maximum of 5 investigational sites in the US.
without concurrent or historical controls.
The primary objective of the study is to generate early feasibility data for the CardiAQ™
Transcatheter Mitral Valve Implant System with the Transfemoral and Transapical Delivery
Systems for the treatment of moderate to severe mitral valve regurgitation in patients who
are considered high risk for mortality and morbidity from conventional open-heart surgery.
The secondary objectives of the study are to evaluate the long-term safety of the device and
the effects of the device on performance, functional, quality of life parameters, and
technical, device, procedural, and individual patient successes.
The study is to be performed at a maximum of 5 investigational sites in the US.
Key Inclusion Criteria:
- NYHA Classification ≥ III
- Left Ventricular Ejection Fraction ≥ 30%
- Mitral Regurgitation ≥ Grade 3+
- Subject meets anatomical and eligibility criteria for the investigational device
Exclusion Criteria:
- See Protocol
We found this trial at
2
sites
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
3400 Spruce St
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
(215) 662-4000
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
Click here to add this to my saved trials